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Summary
Although haemophilia is an expensive disorder, no studies have estimated health care costs for 
Americans with haemophilia enrolled in Medicaid as distinct from those with employer-sponsored 
insurance (ESI). The objective of this study is to provide information on health care utilization and 
expenditures for publicly insured people with haemophilia in the United States in comparison with 
people with haemophilia who have ESI. Data from the MarketScan® Medicaid Multi-State, 
Commercial and Medicare Supplemental databases were used for the period 2004–2008 to 
identify cases of haemophilia and to estimate medical expenditures during 2008. A total of 511 
Medicaid-enrolled males with haemophilia were identified, 435 of whom were enrolled in 
Medicaid for at least 11 months during 2008. Most people with haemophilia qualified for 
Medicaid based on ‘disability’. Average Medicaid expenditures in 2008 were $142,987 [median, 
$46,737], similar to findings for people with ESI. Average costs for males with haemophilia A and 
an inhibitor were 3.6 times higher than those for individuals without an inhibitor. Average costs 
for 56 adult Medicaid enrollees with HCV or HIV infection were not statistically different from 
those for adults without the infection, but median costs were 1.6 times higher for those treated for 
blood-borne infections. Haemophilia treatment can lead to high costs for payers. Further research 
is needed to understand the effects of public health insurance on haemophilia care and 
expenditures, to evaluate treatment strategies and to implement strategies that may improve 
outcomes and reduce costs of care.
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People with haemophilia often require life-long treatment with expensive factor 
concentrates. Complications such as undergoing immune tolerance for an inhibitor, major 
surgery and HIV/AIDS and/or hepatitis treatments can increase the costs of medical care 
still further. The public (or government) sector is particularly affected: 30–40% of male 
patients with haemophilia were covered by Medicare or Medicaid [1–3] and almost two-
thirds of hospital stays with a principal diagnosis of haemophilia during 2008 were covered 
by Medicaid or Medicare (authors’ finding using HCUP-Net [4]). The percentage of 
haemophilia hospital care costs borne by Medicaid and Medicare is much greater than the 
percentage of the population with haemophilia that they cover because high users of health 
care are more likely to be insured by public payers. In 2008, Medicaid and Medicare 
covered 28% of the US population, [5] but were responsible for 58% of all hospital bills [4].
To date, no studies have examined the utilization of health care services and expenditures 
for people with haemophilia who were enrolled in Medicaid or compared them with people 
with employer-sponsored insurance (ESI). Considering the high cost of haemophilia 
treatment and pressures to achieve cost savings, it is important to have a better 
understanding of health care utilization and costs for Medicaid enrollees with haemophilia.
The study objectives are to provide information on health care utilization and expenditures 
of health care for males with haemophilia who were insured by state Medicaid or Children’s 
Health Insurance Program (CHIP) in 2008 and to compare costs with parallel findings for 
male patients with haemophilia covered by ESI, including people enrolled in Medicare with 
employer-paid Medigap plans [6]. In addition, to overall comparisons, this study reports 
differences in health care use and expenditures associated with treatment of an inhibitor 
using a bypassing agent or by infection with HIV and/or HCV, groups reported to have 




The data for this study were obtained from the MarketScan® Medicaid Multi-State databases 
(Thomson Reuters, Inc., New York, NY, USA) for the period 2004–2008. In 2008, the 
Medicaid database covered approximately 5.7 million enrollees who qualify for either 
Medicaid or CHIP in 10 unidentified states. The database does not distinguish whether 
children qualify for CHIP or Medicaid. The database provides information on medical costs, 
as well as demographic information on gender, age, race and annual enrolment, for people 
with a unique identification code that allows tracking of individuals over time. Most of the 
data features of the Medicaid database are the same as those of the MarketScan Commercial 
and Medicare Supplemental and COB databases we used for a parallel study whose results 
are reported here for comparison purposes [6].
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Figure 1 presents the process used to identify individuals with haemophilia using three types 
of medical codes: (i) the International Classification of Disease, Ninth Revision, Clinical 
Modification code (ICD-9-CM); (ii) the Healthcare Common Procedure Coding System; and 
(iii) the National Drug Code using the same criteria employed in a parallel study of 
individuals with ESI [6]. Individuals with an ICD-9-CM code of 286.0 or 286.1 reported in 
at least one inpatient claim or two outpatient claims during 2008 were included if they also 
had a haemophilia procedure code or drug code during 2004–2008 and were male patients. 
Roughly one-third of those that met these criteria were female patients; female patients were 
excluded.
We established six risk groups according to age, type of haemophilia, treatment of an 
inhibitor with bypassing agents (hereafter referred to as individuals with inhibitors) and 
infection with HIV or HCV, using the same codes as in the parallel study [6]: (i) children 
(age <18 years) with haemophilia A and inhibitors; (ii) children with haemophilia A without 
inhibitors; (iii) children with haemophilia B; (iv) adults with haemophilia A with inhibitors; 
(v) adults with haemophilia A or B and blood-borne viral infection without inhibitors; and 
(vi) adults with haemophilia A or B without infection or inhibitors.
Medicaid eligibility criteria
Medicaid covers certain groups of people who also meet Medicaid income and asset criteria, 
which can vary by state [7]: children, adult parents of dependent children, pregnant women 
and elderly people needing nursing home care. Many people with haemophilia are eligible 
without meeting Medicaid criteria because they qualify for Social Security disability 
benefits under supplemental security income (SSI) criteria, which differ. Adults with 
inherited coagulation defects who (i) have experienced spontaneous haemorrhage requiring 
transfusion at least three times during the 5 months prior to adjudication, and (ii) meet SSI 
income and asset criteria may qualify for SSI disability benefits. Children with haemophilia 
may be eligible for SSI if they (i) have repeated spontaneous or inappropriate bleeding, or 
have hemarthrosis with joint deformity, and (ii) meet SSI income and asset criteria [8].
In this analysis, those identified by both disability and poverty codes in the detailed 
enrolment file were classified under poverty, which was considered their primary basis of 
eligibility; so were individuals whose eligibility was recorded as ‘unknown.’ Fourteen per 
cent of all people in the Medicaid database had ‘unknown’ eligibility, compared with 9% of 
people with haemophilia.
Outcome measures
For the purpose of estimating prevalence, all people in the MarketScan Medicaid database 
during 2008 were included. The prevalence of haemophilia was estimated separately by the 
two major Medicaid eligibility criteria – poverty or disability, as defined above. The poverty 
eligibility group represents the standard Medicaid population without enrichment based on 
disability.
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For analyses of health care utilization and expenditures, the sample was further restricted to 
those with at least 11 months of coverage during 2008. We examined various components of 
hospital health care utilization, including the number of inpatient admissions and emergency 
department (ED) visits, the proportion of people who had inpatient admissions and ED 
visits, and the proportion of people who received factor concentrates by risk group.
Health care expenditures were defined as the sum of government payments and individual 
out-of-pocket expenses and presented in 2008 dollars. We reported the mean and median 
estimates of health care expenditures by study group. We also provided significance tests for 
group differences in mean and median estimates, t-test and Wilcoxon tests, respectively.
To calculate total clotting factor expenditures, clotting factor procedure claims from the 
inpatient and outpatient files were combined with outpatient drug claims. Factor 
expenditures may include the expenditure of in-hospital administration. They also include 
expenditures for both factor concentrates and bypassing agents.
Results
All persons with haemophilia
Of the 2.4 million male patients who were included in the 2008 MarketScan Medicaid 
database, 511 were identified as having haemophilia. The prevalence of haemophilia based 
on claims data was 2.2 per 10 000 publicly insured males. The prevalence was significantly 
different by Medicaid eligibility criteria: 7.3 and 1.2 per 10 000 based on disability and 
poverty criteria, respectively. Among 1 422 677 male patients who were covered for at least 
11 months in 2008, 80% qualified because of poverty and 20% because of disability. In 
contrast, among 435 with haemophilia, just 43% qualified because of poverty and 57% 
because of disability. Although adult male patients in the whole Medicaid sample equally 
qualified for Medicaid because of poverty (50%) and disability (50%), adults with 
haemophilia predominantly qualified because of disability (85%). Although most (94%) 
children in the Medicaid database qualified for coverage because of poverty, children with 
haemophilia qualified almost equally because of poverty (58%) and disability (42%).
Of 435 male patients with haemophilia who were covered for at least 11 months in 2008, 
85% (n = 370) had haemophilia A and 15% (n = 65) had haemophilia B (Table 1). A total of 
27 people (7% of the 370 with haemophilia A) were identified as having an inhibitor to 
factor VIII based on their use of bypassing agents. Individuals with haemophilia A were 
slightly more likely to have an inhibitor if they qualified due to poverty (11% of adults and 
7% of children) than if they qualified based on disability (8% and 6%, respectively).
Annual expenditures for people with haemophilia averaged $142,987 in 2008 (Table 2). The 
median expenditure for the average or typical person with haemophilia was $46,737 (for 
additional information on annual costs of care by race, see Table S1). On average, those 
with haemophilia A incurred more costs ($148,215 [median $49,109]) for health care than 
those with haemophilia B ($113,223 [median $34,040]).
GUH et al. Page 4













Among male patients with haemophilia A, average annual total costs for those with an 
inhibitor were 3.6 times higher than total costs for those without an inhibitor ($446,945 vs. 
$124,700; P < 0.01). Similarly, median expenditures for people with an inhibitor were 4.2 
times higher relative to people with an inhibitor ($194,542 vs. $46,737, P < 0.05). Most of 
the expenditures were due to clotting factor, including bypassing agents, which averaged 2.7 
times higher among people with an inhibitor ($287,245 vs. $106,807, P < 0.01), and the 
median clotting factor expenditure was 2.6 times higher ($64,768 vs. $24,852, not 
significant). Clotting factor accounted for 64% of total costs for people with an inhibitor, 
compared with 86% for people without an inhibitor. The difference in total expenditures 
between those with inhibitors and those without inhibitors was accounted for in large part by 
expenditures for other drugs and inpatient care (34% and 11% for people with and without 
an inhibitor, respectively).
Annual average costs were lower for children than adults ($113,867 vs. $194,549, 
respectively, P < 0.01). The difference in median costs between children and adults was 
proportionately even larger ($31,067 vs. $73,291, P < 0.01). Figure 2 presents mean 
expenditures for people with public insurance by 10-year age group (for additional 
information on annual costs of care for people without an inhibitor by blood-borne viral 
infection, see Figure S1). Costs were highest for adults aged 20–29 years.
Children with haemophilia
Among 278 children, 87% had haemophilia A of whom 6% had an inhibitor during 2008 
(Table 3). All boys with an inhibitor received clotting factor (by definition), as did 81% of 
those without an inhibitor. A higher proportion of children with an inhibitor had inpatient 
care services (50% vs. 15%, P < 0.01) and ED visits (81% vs. 53%, P < 0.05) in 2008, 
compared with those without an inhibitor. Among children with at least one ED visit during 
2008, those with an inhibitor visited ED an average of four times, whereas those without an 
inhibitor visited ED three times on average (P < 0.05). Among children without an inhibitor, 
there was no significant difference in the proportion of children who received inpatient care 
services or visited ED and the number of ED visits by type of haemophilia (A or B). A 
higher proportion of children with haemophilia B received clotting factor than did children 
with haemophilia A (94% vs. 81%, P < 0.05).
The average annual expenditure for children with an inhibitor was $509,778 in 2008, 6.1 
times higher than that for children without an inhibitor ($83,765, P < 0.01). Median costs 
were 2.3 times higher for the inhibitor group ($55,038 vs. $23,697). Mean and median costs 
associated with haemophilia A in the absence of an inhibitor ($83,981 [median $23,697]) 
were lower than for those with haemophilia B ($125,522 [median $49,521], P > 0.05), but 
the difference was not statistically significant.
Adults with haemophilia
Among 157 adults with haemophilia, 56 (36%) were treated for HIV or HCV and 11 (7%) 
were treated for an inhibitor (Table 4). Adults with HIV or HCV infection were on average 
10 years older than those without a claims record of infection (P < 0.01). Almost all of them 
(54/56) were >30 years. A higher percentage of adults with an inhibitor had inpatient 
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admission than adults without an inhibitor, but with blood-borne infection (45% vs. 13%, P 
< 0.01). However, the number of ED visits, the proportion of patients who visited EDs, and 
the proportion of patients who received clotting factors did not significantly differ by 
inhibitor or blood-borne viral infection status.
The average costs for adults were roughly twice as high among those treated with bypassing 
agents for inhibitors, $355,552 vs. $184,765, and median costs were more than five times 
higher, $344,607 vs. $62,785. In contrast, there was virtually no difference in mean costs by 
blood-borne viral infection status ($184,765 vs. $178,648, for further information on annual 
costs by components of health care for three different blood-borne viral infection groups see 
Figure S2). On the other hand, median costs were substantially lower for the group without 
HIV or HCV infections ($62,785 vs. $101,446, not significant).
Discussion
The annual mean [median] expenditures for health care during 2008 for Medicaid-enrolled 
males with haemophilia were $142,987 [$46,737]. The average expenditures were lower for 
Medicaid-enrolled children with haemophilia ($113,867 [median $31,067]) than for adults 
($194,549 [median $73,291]). We also found a significant difference in costs for children 
who were treated for inhibitors and those without an inhibitor. Both annual average and 
median costs for children with an inhibitor were six times higher than for children without 
an inhibitor. Among Medicaid-enrolled adults, the differences in mean and median costs by 
inhibitor development were in the same direction and of the same magnitude for median 
costs, but were not statistically significant.
Among adult Medicaid enrollees there was essentially no difference in mean costs by blood-
borne viral infection status. In comparison, Tencer et al.[9] found that the average costs for 
adults with co-infection of HIV or HCV were 59% greater, although only 8% of the 
individuals in their database were enrolled in Medicaid. However, the median expenditures 
in the MarketScan Medicaid sample were 62% higher for those with HIV or HCV, which is 
similar to the finding of Tencer et al.
MarketScan Medicaid and Commercial database findings
The overall prevalence of haemophilia based on claims data was 2.7 times higher among 
Medicaid enrollees than among ESI enrollees (2.2 vs. 0.8 per 10 000 males). The high 
prevalence of haemophilia among Medicaid enrollees who qualified on the basis of 
disability was responsible for this difference. The prevalence of Medicaid enrollees based on 
the poverty criterion is similar to that among people with ESI (1.2 vs. 0.8 per 10 000 males); 
whereas the prevalence among those who qualified based on ‘disability’ was roughly nine 
times higher (7.3 vs. 0.8 per 10 000 male patients). The higher prevalence in the Medicaid 
sample with poverty eligibility reflects the fact that this group is almost exclusively 
comprised of children; the comparable prevalence for children in the ESI sample was 1.4 per 
10 000 male patients [6].
A higher percentage of people with haemophilia enrolled in Medicaid were being treated for 
an inhibitor: 7%, relative to 3% in the ESI sample (Table 5). A higher proportion of people 
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with acute and/or severe conditions have been observed among Medicaid enrollees than in 
the general US population, which is attributed to the fact that selection for the program is 
based on existing health problems or low-socioeconomic status and to differences in access 
to medical care once people are enrolled [1,10–12]. However, there was no significant 
difference in the percentage of adults with HIV or HCV infection by type of insurance (36% 
and 34% among Medicaid enrollees and ESI enrollees respectively).
The rate of hospital-based care utilization was higher for Medicaid enrollees with 
haemophilia than for ESI enrollees (Table 5). More Medicaid enrollees were admitted to the 
hospital and the ED than people with ESI. They were also more frequently admitted to the 
hospital, but not the ED, conditional on having at least one such encounter.
The average annual expenditures for health care were similar for the Medicaid and ESI 
samples, $142,987 and $155,136 respectively (Table 5). Only two study groups statistically 
showed expenditure differences by type of payer: children without an inhibitor and adults 
without blood-borne viral infection. The average annual costs for children enrolled in 
Medicaid without an inhibitor were 0.6 times lower (P < 0.01) and the average annual costs 
for adults enrolled in Medicaid without blood-borne viral infection were 1.5 times higher (P 
< 0.05) than those for each comparison group.
Most of the limitations of this study are inherent in claims data: non-representativeness, 
under-ascertainment of those with mild symptoms and understatement of costs for people 
who have coverage under multiple insurance plans [6]. As people are in the database only if 
they remain in the same health plan, we are not able to track patterns of insurance switching 
over time. In addition, there are limitations specific to the MarketScan Medicaid data. The 
Medicaid sample covers ten unidentified states; we were unable to examine how eligibility 
requirements for covered services affected utilization and expenditures by state [13].
Conclusions
In conclusion, the annual health care expenditures of Medicaid enrollees with haemophilia 
were similar to those of people with ESI. The development of an inhibitor substantially 
increased Medicaid expenditures for children in terms of both mean and median 
expenditures and for adults in terms of median expenditures, although among adults the 
increase in mean expenditures associated with treatment for an inhibitor was smaller and not 
statistically significant. Among adults in Medicaid, blood-borne viral infection was not 
significantly associated with mean expenditures, but was associated with higher median 
expenditures.
This is the first published study that examined the health care utilization and expenditures of 
people with haemophilia enrolled in Medicaid. This study finds that in comparison with 
people with ESI, Medicaid-enrolled people with haemophilia have similar average 
expenditures for health care. However, similar overall expenditures mask greater utilization 
of hospital-based health care by Medicaid enrollees. The lack of difference in annual 
expenditures could be due to lower Medicaid reimbursements for services received.
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Further research is needed to understand the effect of insurance type on haemophilia care as 
opposed to difference in care utilization that reflect differences in the types of people 
enrolled in different types of health insurance. For example, how does insurance type affect 
access and use of home infusion therapy or other health care services? What are the 
differences among payers in the unit costs of health care services such as factor concentrates 
or bypassing agents? Can administrative claims data be used to evaluate the effectiveness of 
treatment strategies? Can such findings be used to increase the effectiveness of health care 
for those with Medicaid coverage as well as reduce the costs to taxpayers of providing what 
may be suboptimal care for people with haemophilia?
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Flow chart of sample selection. C, child; HA, haemophilia A; HB, haemophilia B; B+, 
treatment for an inhibitor with bypassing agents; B−, no treatment for an inhibitor with 
bypassing agents; A, adult; H, haemophilia; V+, with blood-borne viral infection; V−, 
without blood-borne viral infection. *Five adults with both viral infection and inhibitors 
were included in the AHB+ group.
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Annual average health care costs of people with haemophilia who had Medicaid insurance 
by 10-year age group and type of care (clotting factors and all other costs) in 2008 (N = 
435).
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Table 2
Health care utilization and expenditures of male patients with haemophilia by risk group, 2008.
N Median Mean 95th percentile
Health care utilization
 No. of admission w ≥1 admission  95 (22%) 1.0 2.2 6.0
 No. of ED visits w ≥1 visit 224 (51%) 2.0 3.3 9.0
Health care expenditures
 All 435 46 737 142 987 547 397
 Haemophilia A† 370 49 109‡‡ 148 215†† 555 314
 Haemophilia B† 65 34 040 113 223 463 248
 Receiving no bypassing agents‡ 343 46 737‡‡* 124 700††** 437 278
  Clotting factor§ 343 24 852‡‡ 106 807††** 416 158
 Receiving bypassing agents‡ 27 194 542 446 945 1 656 753
  Clotting factor§ 27 64 768 287 245 1 068 799
 Child¶ 278 31 067‡‡** 113 867††** 416 466




represent a 5% and a 1% level of significance, respectively.
†
Statistical tests examine the null hypothesis that people with haemophilia A have the same costs of care as people with haemophilia B.
‡
Statistical tests examine the null hypothesis that people who receive bypassing agents have the same costs of care as people who do not receive 
bypassing agents.
§
Statistical tests examine the null hypothesis that the costs of clotting factor for people who receive bypassing agents are the same as those for 
people who do not receive bypassing agents.
¶
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Table 3




Receiving no bypassing agents 
(CHAB−)†
Receiving bypassing agents 
(CHAB+)‡
No. of children 226 16 36
Age (mean) 9 9¶ 9
Clotting factor
 No. of people (%) 182 (81) 16 (100)‡‡* 34 (94)††*
Emergency department (ED) visits
 No. of people (%) 119 (53) 13 (81)††* 18 (50)††
 Frequency among ED visitors 2.7 4.0¶* 2.8¶
Type of care: N (% of people who received each type of care)
 Inpatient 35 (15) 8 (50)††** 8 (22)††
 Prescription 166 (73) 16 (100)‡‡* 31 (86)††
Total expenditures ($)
 Median 23 697 55 038§§ 49 521§§
 Mean 83 981 509 778¶** 125 522¶
 95th percentile 313 309 4 055 362 590 268
Expenditures for clotting factor ($)
 Median 7548 17 102§§ 27 644§§*
 Mean 64 282 304 599¶** 115 388¶**








Statistical tests examine the null hypothesis that the CHAB− group has the same characteristics as the CHAB+ group.
§
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Table 4
Characteristics of adults with haemophilia by risk group, 2008.
Adults
Receiving no bypassing agents
Receiving bypassing agents 
(AHB+)§
w/o HIV or HCV infection 
(AHV−)†
w HIV or HCV infection 
(AHV+)‡
No. of adults 90 56 11
HIV only – 7 –
HCV only – 27 –
HIV and HCV – 22 –
Age (mean) 28 38¶** 30¶
Clotting factor
 No. of people (%) 75 (83) 48 (86)†† 11 (100)‡‡
Emergency department visits
 No. of people (%) 47 (52) 37 (66)†† 9 (82)††
 Frequency among ED visitors 2.7 4.5¶ 4.7¶
Type of care: N (% of people who received each type of care)
 Inpatient 12 (13) 25 (45)††** 7 (64)††**
 Prescription 55 (61) 23 (41)††* 8 (73)††
Total expenditures ($)
 Median 62 785 101 446§§ 344 607§§
 Mean 184 765 178 648¶ 355 552¶
 95th percentile 774 684 599 417 1 349 718
Expenditures for clotting factor ($)
 Median 56 621 59 627§§ 141 898§§
 Mean 179 253 150 874¶ 262 004¶








Statistical tests examine the null hypothesis that the AHV− group has the same characteristics as the AHV+ group.
‡
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Table 5





No. of people        1164          435   –
No. of people w an inhibitor (% of haemophilia A)            27 (7%)            30 (3%) <0.01‡
No. of people with admission (%)            95 (22%)          164 (14%) <0.01‡
 No. of admission w ≥1 admission(s)           2.2 (2.2)           1.4 (1.0) <0.01†
No. of people with ED visit (%)          224 (51%)          379 (33%) <0.01‡
 No. of ED visits w ≥1 visit (s)           3.3 (4.5)           2.8 (6.4)   0.29†
Health care expenditures (mean[median]) Ratio (Medicaid/ESI)¶ [6]
All 142 987 [46 737] 155 136 [73 548]   0.9† [0.6§**]
Children 113 867 [31 067] 150 680 [72 374]   0.8† [0.4§**]
 Haemophilia A
  w/o an inhibitor   83 981 [23 697] 142 057 [73 659]   0.6†**[0.3§**]
  w an inhibitor 509 778 [55 038] 831 866 [461 527]   0.6 [0.1§]
 Haemophilia B 125 522 [49 521]   92 546 [36 177]   1.4†[1.4§]
Adult 194 549 [73 291] 159 310 [76 088]   1.2†[1.0§]
 w/o an inhibitor
  w/o blood-borne viral infection 184 765 [62 785] 125 861 [43 968]   1.5†*[1.4§]
  w blood-borne viral infection 178 648 [101 446] 188 056 [116 207]   0.9†[0.9§]












To compare mean and median estimates, we used t-tests and Wilcoxon–Mann–Whitney test, respectively.
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